Ascentage Pharma Group International (6855.HK)
Develops cancer and viral infection drugs in clinical trials for patients in China.
35.30+0.00%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-51.0%
The outlook
Ascentage Pharma has strong analyst backing with a consensus buy rating, and the average price target sits roughly 132% above the current price. The stock is trading well below both its 50- and 200-day moving averages and sits near the lower end of its 52-week range, suggesting a downtrend. Overall sentiment is neutral despite the bullish analyst view.
What’s behind the score
Analyst consensusStrong Buy — 1.1 avg of 5 analysts
Price trendBelow its 50- & 200-day averages
52-week range8% of the way from its 52-week low to high
Price targetAvg target +132% vs current price
Analyst price target
~12-month · 5 analysts81.87average target+131.9% vs now
Now 35.30
Low 43.69High 107.49
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$13.18B
52-wk high
95.35
52-wk low
30.00
50-day avg
35.76
200-day avg
48.81
Trailing P/E
—